FDA Grants Marketing Authorization For Siemens ELF Test
Siemens Healthineers’ Enhanced Liver Fibrosis (ELF) Test was granted marketing authorization under the De Novo review pathway.
Read MorePosted by Chris Wolski | Aug 24, 2021 | Unknown Origin & Other Cancer Types |
Siemens Healthineers’ Enhanced Liver Fibrosis (ELF) Test was granted marketing authorization under the De Novo review pathway.
Read MorePosted by Chris Wolski | Jun 17, 2021 | Diabetes & Metabolic Diseases |
Researchers have identified a noninvasive biomarker that can identify patients at risk of NAFLD complications using a simple blood test.
Read MorePosted by Laurie Bonner | Mar 26, 2021 | Disease States |
Early detection, monitoring, and noninvasive diagnostic testing are essential to controlling this epidemic.
Read MorePosted by Melanie Hamilton-Basich | Feb 25, 2021 | Prenatal Testing |
The method uses a DNA biomarker to easily screen pregnant women for harmful prenatal environmental contaminants like air pollution linked to childhood illness and developmental disorders.
Read MorePosted by Melanie Hamilton-Basich | Feb 18, 2021 | Hematology & Serology, Research |
New research has shown that results of blood tests routinely performed by GPs everywhere contain a hidden fingerprint that can identify people silently developing potentially fatal liver cirrhosis.
Read More